Company Encyclopedia
View More
name
Privia Health
PRVA.US
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It offers technology and population health tools to enhance providers’ workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives.
384.02 B
PRVA.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
B
Health Care ServicesIndustry
Industry Ranking11/80
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE2.74%C
    • Profit Margin0.89%C
    • Gross Margin10.99%E
  • Growth ScoreB
    • Revenue YoY19.01%B
    • Net Profit YoY41.66%B
    • Total Assets YoY17.93%A
    • Net Assets YoY15.19%A
  • Cash ScoreA
    • Cash Flow Margin11243.29%A
    • OCF YoY19.01%B
  • Operating ScoreA
    • Turnover1.64A
  • Debt ScoreC
    • Gearing Ratio43.54%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Privia Health Group (PRVA) Gets a Buy from RBC Capital

    RBC Capital analyst Sean Dodge initiated coverage on Privia Health Group with a Buy rating and a $30 price target. The stock closed at $24.22. Canaccord Genuity also issued a Buy rating, while Barclays maintained a Hold rating. Dodge is ranked #9888 out of 10072 analysts on TipRanks.

    Tip Ranks·
    US
    PRVA
    +5.28%
    Tip Ranks·
    US
    PRVA
    +5.28%

    BMO Capital Highlights Privia Health Group’s Strong Growth Potential and Differentiated Risk Management in Value-Based Care

    BMO Capital has initiated a Buy rating for Privia Health Group (PRVA), citing its strong long-term earnings growth potential and effective value-based care approach. The firm highlights Privia's stable earnings, impressive free cash flow, and significant expansion opportunities, projecting over 20% EBITDA growth in the next two years. Privia's unique risk management strategy, which involves sharing risk with payers and providers, is expected to enhance profitability. Canaccord Genuity also reiterated a Buy rating with a $34.00 price target.

    Tip Ranks·
    US
    PRVA
    +5.28%
    Tip Ranks·
    US
    PRVA
    +5.28%

    Privia Health’s Earnings Call Highlights Robust Growth

    Privia Health Group, Inc. reported strong Q3 earnings, with practice collections up 27.1% year-over-year to $940.4 million and adjusted EBITDA rising 61.6% to $38.2 million. The company achieved a 9.4% savings rate in the Medicare Shared Savings Program and expanded its provider base by 13.1%. Despite challenges in the Medicare Advantage capitation model, Privia maintains a strong cash position of $409.9 million and has issued conservative Q4 guidance. Looking ahead, the company anticipates significant growth in practice collections and EBITDA by 2025.

    Tip Ranks·
    US
    PRVA
    +5.28%
    Tip Ranks·
    US
    PRVA
    +5.28%

    Privia Health Group (NASDAQ:PRVA) Hits New 12-Month High - Should You Buy?

    Privia Health Group (NASDAQ:PRVA) reached a new 52-week high of $26.51, closing at $26.02 with a trading volume of 83,139 shares. Analysts have mixed ratings, with Barclays raising the target price to $22.00 and Zacks upgrading to a 'hold'. The stock has a consensus rating of 'Moderate Buy' and a target price of $28.91. Institutional investors own 94.48% of the stock. The company reported $0.10 EPS and $213.61 million in revenue for the last quarter.

    Market Beat·
    US
    PRVA
    +5.28%
    Market Beat·
    US
    PRVA
    +5.28%

    Privia Health | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 580.42 M

    LB filings·
    US
    PRVA
    +5.28%
    LB filings·
    US
    PRVA
    +5.28%